Navigation Links
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Date:9/21/2010

ebilitating disease," said William H. Ludlam, MD, PhD, Director, Seattle Pituitary Center at the Swedish Neuroscience Institute in Seattle, WA.  "The results of this study suggest that pasireotide may help patients achieve biochemical control of their Cushing's disease and its symptoms by directly targeting the pituitary tumor that triggers excess cortisol production."

PASPORT-CUSHINGS (PASireotide clinical trial PORTfolio - CUSHING'S disease) is the largest randomized study to evaluate a medical therapy in patients with Cushing's disease(1). The trial is part of a large-scale global clinical development program to assess the efficacy and safety of SOM230 in a range of pituitary and neuroendocrine tumors(6).

"Positive results from this trial bring us one step closer to providing physicians with a new treatment option to offer people living with the physically and emotionally debilitating symptoms associated with Cushing's disease," said Herve Hoppenot, President, Novartis Oncology.

These data will form the basis for the first regulatory filing of SOM230 planned this year. SOM230 has orphan drug designation for Cushing's disease in the US and Europe(7),(8). In the US, orphan drugs are those developed to treat diseases affecting fewer than 200,000 people(9). In Europe, orphan drugs are those developed to treat conditions affecting fewer than five in 10,000 people(8).

Study detailsPASPORT-CUSHINGS is a prospective Phase III study of 162 patients conducted at 68 sites in 18 countries. The study evaluated the efficacy and safety of SOM230 in patients with persistent or recurrent Cushing's disease, as well as in patients with newly diagnosed Cushing's disease who are not candidates for surgery(1),(10).

Patients with primarily moderate to severe hypercortisolism were randomized to receive SOM230 subcutaneous (sc) injection in doses of 600ug (n=82) or 900ug (n=80) twice daily. The primary endpoint was the proportion of patients who
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, 2015 ... 47.54 billion by 2020, according to a new study by Grand ... II diabetes and the presence of high unmet needs in emerging ... China are expected to be two of the most ... lifestyle induced diseases such as obesity and growing global geriatric population ...
(Date:6/29/2015)... CITY, Mo. , June 29, 2015  Missouri ... the 2015 first quarter data from the state,s real-time, ... (NPLEx). States across the United ... Missouri one of 31 across the country ... attempted pseudoephedrine (PSE) purchases at the point of sale.  ...
(Date:6/29/2015)... KING OF PRUSSIA, Pa. , June 29, 2015 ... Alsharabati, MD, University of Alabama at Birmingham, ... 2015 Interlaken Leadership Award for ... global awards program provides monetary grants and/or product supply ... potential role of immunoglobulin (Ig) therapy in the treatment ...
Breaking Medicine Technology:Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 2Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 3Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 4CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient 2CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient 3
... 5, 2011 In its April issue, published this ... magazine has announced the winners of the fourteenth annual ... (Logo:  https://photos.prnewswire.com/prnh/20101214/LA16070LOGO) Sponsored by MD+DI ... the premier awards program for the medical technology community. ...
... April 5, 2011 RESMED INC. (NYSE: RMD ... will release its results for the third quarter and nine ... press release with ResMed,s results will be issued after 1:00 ... call and webcast to review its results, market trends, and ...
Cached Medicine Technology:37 Innovative Products Win Medical Design Excellence Awards 237 Innovative Products Win Medical Design Excellence Awards 337 Innovative Products Win Medical Design Excellence Awards 4ResMed Announces Conference Call and Webcast to Discuss Third Quarter 2011 Results 2
(Date:6/29/2015)... ... June 30, 2015 , ... The National ... 2015-2016 inductee into its VIP Woman of the Year Circle. She is recognized ... networking organization exclusively for professional women, boasting more than 700,000 members and over ...
(Date:6/29/2015)... ... June 30, 2015 , ... Leaders in post acute care ... premier thought leadership symposiums, “Harmony 2015” hosted by Massachusetts-based Harmony Healthcare International. ... management and corporate personnel representing the skilled nursing and assisted living markets. ...
(Date:6/29/2015)... ... June 30, 2015 , ... The United States Equestrian ... (KORT) as it becomes the Official Physical and Occupational Therapists of the U.S. Eventing ... Kentucky Three-Day Event presented by Land Rover. , “The USEF is pleased to ...
(Date:6/29/2015)... , ... June 30, 2015 , ... With thousands of ... its involvement in a much-needed autism support center, planned at Utah Valley University, in ... formal approval for the center and the building in which it will be housed. ...
(Date:6/29/2015)... ... June 30, 2015 , ... Career ... new website intended for executives and administrators with hospitals, healthcare providers, and insurance ... final product is a result of comprehensive research and implementation of web design ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Melanie Richards, DMD, of Powdersville Pediatric Dentistry, Into its VIP Woman of the Year Circle 2Health News:Gov. Mark Parkinson, President and CEO of AHCA/NCAL to Give Keynote Address at Harmony 2015 2Health News:Gov. Mark Parkinson, President and CEO of AHCA/NCAL to Give Keynote Address at Harmony 2015 3Health News:KORT Physical Therapy Announces Partnership with The United States Equestrian Federation 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 3Health News:Career Step Launches New Website to Better Meet Needs of Partners, Clients and Others Searching for Corporate Training Solutions 2
... 15 Yearbook photos capture school,portraits for years to ... photo that they would prefer to erase -- and ... photos this year, and to,kick-off the launch of the ... CLEAR(R) is inviting teens to,"Erase Their Worst Year Book ...
... Md., Sept. 15 Two new guides to,help consumers ... today by the U.S. Department of Health and Human ... blood clots are harmful but deep vein thrombosis, a ... body, most commonly in the lower leg or,thigh, is ...
... the American College of Physicians (ACP) says that because ... "have and will continue to have" in the internal ... would support their role. The Role of International ... that ACP feels would support that role. , IMGs ...
... Investor Purchases $9MM Convertible Notes, NEW YORK, Sept. ... CTICD , and MTA: CTIC) today announced,that a ... newly issued 10% Convertible Senior Notes due 2012, with ... a put right subject to,price, volume and other requirements ...
... current 3-hour limit, international researchers find , , SUNDAY, Sept. ... the clot-dissolving drug tPA could safely be used within ... can be extended to four-and-a-half hours. , "We now ... Nils Wahlgren, a neurology professor at the Karolinska Institute ...
... For the first time, researchers have identified variations in ... diseases disproportionately affecting African-Americans. This work was conducted by ... by NIH-funded investigators at the Johns Hopkins University. The ... Nature Genetics and will be published in ...
Cached Medicine News:Health News:CLEAN & CLEAR(R) Is Inviting Teens to 'Erase Their Worst Yearbook Picture' With The NEW CLEAN & CLEAR(R) Advantage(R) Blackhead Eraser(TM) Exfoliating Cleanser 2Health News:AHRQ Releases Two New Resources to Help Consumers and Clinicians Prevent Dangerous Blood Clots 2Health News:AHRQ Releases Two New Resources to Help Consumers and Clinicians Prevent Dangerous Blood Clots 3Health News:US must enact measures to support the role of IMGs in US health-care delivery, says ACP 2Health News:Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase Up to $18 Million of Senior Convertible Notes 2Health News:Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase Up to $18 Million of Senior Convertible Notes 3Health News:Later Use of Clot-Buster After Stroke Possible: Study 2Health News:Newly found gene variants account for kidney diseases among African-Americans 2Health News:Newly found gene variants account for kidney diseases among African-Americans 3Health News:Newly found gene variants account for kidney diseases among African-Americans 4
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
The Gizmo male external catheter is a latex catheter that uses a single-sided adhesive strip....
... Rochester Medical's line of ... intermittent catheters you would ... four product configurations - ... antibacterial hydro - are ...
... The Mentor Freedom Pak Seven ... packaged week's supply of Freedom ... kit all 100% latex-free ... wipes for your convenience and ...
Medicine Products: